Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

BACKGROUND: KRAS mutations occur in 35–45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstrea...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Nichelatti, Michele, Molinari, Francesca, De Dosso, Sara, Saletti, Piercarlo, Martini, Miriam, Cipani, Tiziana, Marrapese, Giovanna, Mazzucchelli, Luca, Lamba, Simona, Veronese, Silvio, Frattini, Milo, Bardelli, Alberto, Siena, Salvatore
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2009
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2750753/
https://ncbi.nlm.nih.gov/pubmed/19806185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0007287
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires